Mabion S.A. (WSE:MAB)
Poland
· Delayed Price · Currency is PLN 7.90
-0.15 (-1.86%)
Mar 9, 2026, 5:02 PM CET
Mabion Revenue
Mabion had revenue of 4.08M PLN in the quarter ending September 30, 2025, with 691.47% growth. This brings the company's revenue in the last twelve months to 14.81M, down -86.63% year-over-year. In the year 2024, Mabion had annual revenue of 69.02M, down -54.50%.
Revenue (ttm)
14.81M
Revenue Growth
-86.63%
P/S Ratio
8.78
Revenue / Employee
70.53K
Employees
213
Market Cap
130.11M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Poltreg | 250.00K |
| Molecure | 5.86M |
| NanoGroup | -6.90K |
| Urteste | 1.80M |
| Synthaverse | 71.76M |
| BIOTON | 282.52M |
| Pharmena | 1.58M |
| Captor Therapeutics Spolka Akcyjna | 7.57M |
Mabion News
- 5 years ago - Spark Therapeutics Further Strengthens Technical Expertise with Appointment of Cynthia Pussinen as Chief Technical Officer - GlobeNewsWire
- 5 years ago - Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease - GlobeNewsWire
- 6 years ago - GAMCO Investors Exits Viacom, Spark Therapeutics - GuruFocus
- 6 years ago - Regulators Give Roche Green Light For $4.3B Spark Therapeutics Acquisition - Benzinga
- 6 years ago - Roche to complete $4.3 billion Spark deal as regulators give all clear - Reuters
- 6 years ago - U.S. antitrust enforcers give Roche approval to buy Spark Therapeutics - Reuters
- 6 years ago - Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product - GlobeNewsWire
- 6 years ago - FTC staff recommends approval of Roche deal for Spark: report - Reuters